Acute and Chronic Metabolic Flexibility in Individuals Living With Obesity: The i-FLEX Study

Obesity Clinical Trial

— i-FLEX  

Official title:

Sprint Interval Training: Insulin Sensitivity and Acute-Chronic Metabolic Flexibility in Individuals Living With Obesity: The i-FLEX Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03527446
• Other study ID #: UNewBrunswick
• Status: Completed
• Phase: N/A
• Start date: July 3, 2018
• Est. completion date: February 28, 2020

Study information

• Verified date: March 2020
• Source: University of New Brunswick
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Regular exercise is a cornerstone in the prevention and the management of cardio-metabolic risk factors. Some of the beneficial effect of exercise training occurs through metabolic flexibility' enhancement. Metabolic flexibility is the ability to respond or adapt to conditional changes in metabolic demand, and previous literature has shown that individuals living with obesity have an impaired metabolic flexibility compared to lean individuals. However, there is a lack of empirical evidence on the impact of sprint interval training on metabolic flexibility and whether this translates into clinically meaningful outcomes.

This study will evaluate the impact of 4-week sprint interval training in normal weight individuals as well as individuals living with obesity on acute and chronic metabolic flexibility, irisin secretion and insulin sensitivity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: February 28, 2020
• Est. primary completion date: February 28, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years to 60 Years

Eligibility

Inclusion Criteria:

• Adults (Ages 19-60)

• Physically inactive for individuals living with obesity (not meeting Canadian Physical Activity Guidelines)

• Normal Weight (BMI = 18.5 < 25.0 km/m2)

• Obesity (BMI = 30.0 km/m2)

Exclusion Criteria:

• Individuals with Type 2 Diabetes.

• Individuals with impaired glucose tolerance.

• Individuals living with obesity that partake in regular exercise training / meet the Canadian Physical Activity Guidelines.

• Individuals with a condition or injury that may impact the ability to perform exercise or may be worsened by exercise.

• Individuals currently being treated with corticosteroids or atypical antipsychotics, as these agents significantly influence carbohydrate metabolism.

• have experienced >10% weight loss or enrolled in weight loss program within six months of enrolment.

• require use of medication(s) known to affect insulin sensitivity or secretion within the last 30 days.

• Medication(s) known to cause weight gain.

• weight loss medication(s).

Related Conditions & MeSH terms

• Exercise
• Hypersensitivity
• Insulin Resistance
• Insulin Sensitivity
• Obesity
• Obesity; Endocrine

Intervention

Behavioral:
• Sprint Interval Training
The 4-week sprint interval intervention will consist of a work-rest ratio of four 30-s intervals of exercise at maximal capacity and 4-min of passive recovery at 50% of maximal capacity between intervals. There will be three sessions per week.

Locations

Country	Name	City	State
Canada	University of New Brunswick - Kinesiology	Fredericton	New Brunswick

Sponsors (1)

Lead Sponsor	Collaborator
University of New Brunswick

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Muoio DM. Metabolic inflexibility: when mitochondrial indecision leads to metabolic gridlock. Cell. 2014 Dec 4;159(6):1253-62. doi: 10.1016/j.cell.2014.11.034. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Metabolic Flexibility	Chronic and acute metabolic flexibility will be quantified from the respiratory quotient (RQ) at rest and from the respiratory exchange ratio (RER) during a 4-6 minutes steady rate exercise bout.	Baseline and post-intervention (4 weeks)
Primary	Change in Insulin Sensitivity	Insulin sensitivity will be measure with the Matsuda Index	Baseline and post-intervention (4 weeks)
Secondary	Change in Irisin	This hormone will be quantified in the plasma during one acute session of exercise.	Baseline and post-intervention (4 weeks)